english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Nasal naloxone (Nyxoid°): effective in opioid overdoses

A new naloxone-containing nasal spray (Nyxoid°) has been authorised in the European Union for emergency use in medical and non-medical settings in adults and adolescents aged 14 years and over. How do Prescrire's editors rate this product in its new form?
1 February 2022

Eosinophilic oesophagitis: the advantages of orodispersible budesonide (Jorveza°)

Orodispersible tablets of budesonide are being proposed for the treatment of eosinophilic oesophagitis, an immune-mediated disease. Budesonide is a corticosteroid already used in other forms and in other settings. The orodispersible form is better suited to oesophageal disease, with demonstrated efficacy against symptoms.
1 February 2022

Pneumococcal vaccine: choose on the basis of the child's age

There have been reports in France of infants receiving unconjugated pneumococcal polysaccharide vaccine (Pneumovax°), which is ineffective at this age, instead of the pneumococcal conjugate vaccine (Prevenar°), as a result of prescribing or dispensing errors.
1 February 2022

A critical eye

 Editorial  Welcome to the new, redesigned Prescrire International: a "critical eye" on drugs in Europe, with patients' interests front and centre.
1 January 2022

Crizanlizumab (Adakveo°) to prevent vaso-occlusive crises in sickle-cell disease: No proven clinical advantages

FEATURED REVIEW Is crizanlizumab more effective than hydroxycarbamide for patients with sickle-cell disease? Does it prevent vaso-occlusive crises and their serious complications when hydroxycarbamide is not sufficiently effective or cannot be used? What is its adverse effect profile?
Full review (5 pages) available for download by subscribers.
1 January 2022

In the January issue of Prescrire International: adverse effects of lamotrigine and biotin

FREE DOWNLOAD In our sample page from this month's issue, cardiac arrhythmias with lamotrigine, and biotin supplements' interference with laboratory tests.
Full text available for free download.
1 January 2022

Dravet syndrome: fenfluramine (Fintepla°) for children is unacceptable

Giving fenfluramine to children with Dravet syndrome (a rare and severe form of epilepsy), including those whose seizures remain frequent despite optimised treatment, increases the incidence of the most serious seizures and exposes them to a risk of serious cardiovascular adverse effects.
1 January 2022

Vitamin D drops for infants: mistakes to avoid

Errors and accidents are frequent with vitamin D supplied in dropper bottles. These include handling by children, eye exposure and, above all, overdose due to a mistake or related to a defective dropper bottle.
1 January 2022

Alzheimer's: yet another unwelcome drug

Despite aducanumab's lack of demonstrated efficacy in Alzheimer's disease, the scene is set to raise the hopes of patients and those close to them, and above all to promote the interests of the company and its shareholders.
1 January 2022

Dapagliflozin (Forxiga°) and chronic heart failure

FEATURED REVIEW An alternative to the sacubitril + valsartan combination, with the serious adverse effects common to all gliflozins.
Full review (3 pages) available for download by subscribers.
1 December 2021

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90